In vivo absorption of didanosine formulated in pellets composed of chitosan microspheres

In Vivo

Volumn 28, Issue 6, 2014, Pages 1045-1050

  Severino, Patrícia ^a,b,c   Da Silva, Classius Ferreira ^d   Dalla Costa, Teresa Cristina T ^e   Silva, Heloisa ^d,f   Chaud, Marco V ^g   Santana, Maria Helena A ^a   Souto, Eliana B ^h  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b TIRADENTES UNIVERSITY   (Brazil)

^c Technological Research Institute   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^g UNIVERSITY OF SOROCABA   (Brazil)

^h UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Chitosan microspheres; Didanosine; In vivo; Male adult dogs; Pellets; Pharmacokinetics

Indexed keywords

CHITOSAN; DIDANOSINE; MICROSPHERE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TABLET;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL ADHESION; CELL MEMBRANE; CHEMICAL COMPOSITION; CONTROLLED DRUG RELEASE; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG GRANULE; DRUG HALF LIFE; DRUG PENETRATION; ELIMINATION RATE CONSTANT; IN VIVO STUDY; INTESTINE CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; SWALLOWING; ABSORPTION; ANIMAL; CHEMISTRY; MEDICINAL CHEMISTRY; TABLET;

ABSORPTION, PHYSIOLOGICAL; ANIMALS; ANTI-HIV AGENTS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DIDANOSINE; DOGS; MALE; MICROSPHERES; TABLETS;

EID: 84936750150     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Amole CD, Brisebois C, Essajee S, Koehler E, Levin AD, Moore MC, Ripin DHB, Sickler JJ and Singh IR: Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries. JAIDS Journal of Acquired Immune Deficiency Syndromes 57: S100-S103, 2011.
2. Aschacher T, Sampl S, Käser L, Bernhard D, Spittler A, Holzmann K and M. B: The combined use of known antiviral reverse transcriptase inhibitors AZT and DDI induce anticancer effects at low concentrations. Neoplasia 14: 44-53, 2012.
3. Bashir Khan A and Sharnagat Thakur R: Formulation and Evaluation of Mucoadhesive Microspheres of Tenofovir Disoproxil Fumarate for Intravaginal Use. Current drug delivery 11: 112-122, 2014.
4. Chang H-M, Tsai H-C, Lee S, Wann S-R and Chen Y-S: Noncirrhotic portal hypertension associated with didanosine: a case report and literature review. Jpn J Infect Dis 65: 61-65, 2012.
5. da Silva CF, Severino P, Martins F, Chaud MV and Santana MHA: The intestinal permeation of didanosine from granules containing microspheres using the everted gut sac model. Journal of microencapsulation 26: 523-528, 2009.
6. Derakhshandeh K and Fathi S: Role of chitosan nanoparticles in the oral absorption of Gemcitabine. International journal of pharmaceutics 437: 172-177, 2012.
7. Guzman-Villanueva D, El-Sherbiny IM, Herrera-Ruiz D and Smyth HD: Design and in vitro evaluation of a new nanomicroparticulate system for enhanced aqueous-phase solubility of curcumin. BioMed research international 2013.
8. Ko J, Park H, Hwang S, Park J and Lee J: Preparation and characterization of chitosan microparticles intended for controlled drug delivery. International journal of pharmaceutics 249: 165-174, 2002.
9. Koukaras EN, Papadimitriou SA, Bikiaris DN and Froudakis GE: Insight on the formation of chitosan nanoparticles through ionotropic gelation with tripolyphosphate. Molecular pharmaceutics 9: 2856-2862, 2012.
10. Lacerda L, Parize AL, Fávere V, Laranjeira MCM and Stulzer HK: Development and evaluation of pH-sensitive sodium alginate/chitosan microparticles containing the antituberculosis drug rifampicin. Materials Science and Engineering: C 39: 161-167, 2014.
11. Liu H, Ma Y, Su Y, Smith MK, Liu Y, Jin Y, Gu H, Wu J, Zhu L and N. W: Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-analysis. Clin Infect Dis In press2014.
12. Menéndez-Arias L and M. A: Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antiviral Res 102: 70-86, 2013.
13. Pasqualone F: Bristol-Myers Squibb clarification on didanosine supply. Lancet 376: 1054, 2010.
14. Ramana LN, Sharma S, Sethuraman S, Ranga U and Krishnan UM: Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic systems. Biochimica et Biophysica Acta (BBA)- General Subjects 1840: 476-484, 2014.
15. Russo E, Gaglianone N, Baldassari S, Parodi B, Cafaggi S, Zibana C, Donalisio M, Cagno V, Lembo D and Caviglioli G: Preparation, characterization and in vitro antiviral activity evaluation of foscarnet-chitosan nanoparticles. Colloids and Surfaces B: Biointerfaces 118: 117-125, 2014.
16. Sanjai C, Kothan S, Gonil P, Saesoo S and Sajomsang W: Chitosan-triphosphate nanoparticles for encapsulation of superparamagnetic iron oxide as an MRI contrast agent. Carbohydrate polymers 104: 231-237, 2014.
17. Santana MHA, da Silva CF and F. M: Mucoadhesive granules containing chithosan nano-and/or microspheres and process for obtaining said mucoadhesive granules. (WIPO ed.). Brazil, 2008.
18. 18 Schaffazick SR, Guterres SS, Freitas Ld and Pohlmann AR: Caracterização e estabilidade físico-química de sistemas poliméricos nanoparticulados para administração de fármacos. Química Nova 26: 726-737, 2003.
19. Severino P, de Oliveira GG, Ferraz HG, Souto EB and Santana MH: Preparation of gastro-resistant pellets containing chitosan microspheres for improvement of oral didanosine bioavailability. Journal of Pharmaceutical Analysis 2: 188-192, 2012.
20. Severino P, de Oliveira GGG, Ferraz HG, Souto EB and Santana MH: Preparation of gastro-resistant pellets containing chitosan microspheres for improvement of oral didanosine bioavailability. J Pharm Anal 2: 188-192, 2012.
21. Severino P, Silva H, Souto EB, Santana MH and Dalla Costa TC: Analysis of in vivo absorption of didanosine tablets in male adult dogs by HPLC. J Pharm Anal 2: 29-34, 2012.
22. Sinha V, Singla A, Wadhawan S, Kaushik R, Kumria R, Bansal K and Dhawan S: Chitosan microspheres as a potential carrier for drugs. International Journal of Pharmaceutics 274: 1-33, 2004.
23. Soppimath KS, Aminabhavi TM, Kulkarni AR and Rudzinski WE: Biodegradable polymeric nanoparticles as drug delivery devices. Journal of controlled release 70: 1-20, 2001.
24. Steckel H and Mindermann-Nogly F: Production of chitosan pellets by extrusion/spheronization. European Journal of Pharmaceutics and Biopharmaceutics 57: 107-114, 2004.
25. Velasque LS, Estrela RC, Suarez-Kurtz G and CJ. S: A new model for the population pharmacokinetics of didanosine in healthy subjects. Braz J Med Biol Res 40: 97-104, 2007.
26. Wan S, Sun Y, Sun L and Tan F: Chitosan microparticles for oral bioavailability improvement of the hydrophobic drug curcumin. Die Pharmazie-An International Journal of Pharmaceutical Sciences 67: 525-528, 2012.